Scandinavian journal of clinical and laboratory investigation (2020 Dec)
Issue 8 p. 687-693 issn:1502-7686)
Inflammation is one of the hallmarks of cancer and plays a crucial role in the development and progression. The objective of the present study was to investigate if high serum YKL-40 is related to poor prognosis in cervical cancer (CC) patients. A prospective biomarker study of 116 patients with CC (FIGO stage Ia: ?=?4; Ib: ?=?55; II: ?=?26; III: ?=?26; IV: ?=?5) and 152 patients with cervical intraepithelial neoplasia (CIN). The patients received primary surgery, radiotherapy and chemotherapy according to standard guidelines during the period 2001-2004. Seventy patients died during the follow-up period (median 117?months, range 104-131). Serum concentrations of YKL-40 were measured by ELISA. Serum concentrations of YKL-40 were increased (?<?.001) in CC patients (median 76?µg/L, IQR 45-148) compared to CIN patients (44?µg/L, IQR 30-61) and healthy women (41?µg/L, IQR 29-58). YKL-40 was elevated (>age-corrected 95th percentile of YKL-40 in healthy women) in 30 (26%) of the CC patients. Univariate Cox analysis demonstrated that YKL-40 (included as a log-transformed continuous variable (base 2)) was associated with recurrence-free survival (RFS) (HR = 1.48, 95% CI: 1.11-1.98, ?=?.008) and overall survival (OS) (HR = 1.74, 1.44-2.10, ?<?.0001). Multivariate Cox analysis showed that stage (II?+?III vs. I: HR = 2.92, 1.37-6.20, ?=?.005), YKL-40 (HR = 1.35, 1.06-1.73, ?=?.018) and age (HR = 1.56, 1.21-1.99, ?=?.0005) were independent prognostic variables of OS. During treatment, a 2-fold increase in YKL-40 compared to baseline level was associated with short RFS (HR = 1.87, 1.27-2.77, ?=?.0016) and OS (HR = 1.78, 1.26-2.50, ?=?.0010). Serum YKL-40 is an independent biomarker of OS in patients with cervical cancer.
Forfattere: Roslind A, Palle C, Johansen JS, Christensen IJ, Nielsen HJ, Mosgaard BJ
